We noticed you are on our AU page. Want to switch regions? Choose from the options:

Prostate Cancer

DASL-HiCaP

The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.

Trial overview

Topic

Prostate cancer

Description

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Eligibility criteria

  • Men after 18 years or older
  • Planned for Primary Radiotherapy and judged to be at very high risk for recurrence
  • OR Post-Radical Prostatectomy within 365 days and planned for radiotherapy with PSA great than or equal to 0.1ng/mL that has risen or remained stable (within <0.5ng/mL), judged to be at very high risk of recurrence

Study details

This is a randomised controlled trial, which means that, in addition to best standard treatments, half the participants on the study will receive darolutamide, and the other half will receive placebo, a substance that has no active medicine in it.

The main aim of the study is to see if the addition of the study medication (darolutamide) to standard treatment is better for improving the outcomes of people with your type of prostate cancer compared to standard treatment.

Participants are followed up regularly for 4-7 years.

Further information

For more information regarding this clinical trial click here.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.